Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsMary Murray, MD, FACOG
Clinical InstructorAbout
Research
Publications
2026
Does resection of cavity shave margins impact survival in breast cancer patients?
Chagpar A, Gallagher K, Garcia-Cantu C, Howard-McNatt M, Levine E, Gass J, Lum S, Willis A, Brown E, Fenton A, Mendiola A, Murray M, Solomon N, Senthil M, Ollila D, Edmonson D, Lazar M, Namm J, Dupont E, Authors S. Does resection of cavity shave margins impact survival in breast cancer patients? Journal Of Clinical Oncology 2026, 44: 513-513. DOI: 10.1200/jco.2026.44.16_suppl.513.Peer-Reviewed Original ResearchCavity shave marginsDisease-free survivalRe-excision ratesLocal recurrence rateRe-ExcisionShave marginsFinal marginsRecurrence rateMedian invasive tumor sizeSmall-volume residual diseaseRates of radiation therapyInvasive tumor sizePositive final marginsPositive margin rateMedian Follow-UpSingle center studyBreast cancer patientsCox proportional hazards modelsYears of ageProportional hazards modelRandomized Controlled TrialsResidual diseaseNeoadjuvant chemotherapyNegative marginsRadiation therapyUtilization of Tumor Markers for Intraoperative Specimen Radiography Does Not Decrease the Rate of Margin Positivity in Breast Conservation Surgery (BCS).
Prasad R, Brainerd M, Ortega C, Gabra J, Mangira C, Brett-Morris A, Mamone C, Fenton A, Murray M. Utilization of Tumor Markers for Intraoperative Specimen Radiography Does Not Decrease the Rate of Margin Positivity in Breast Conservation Surgery (BCS). The American Surgeon 2026, 31348261448903. PMID: 42080622, DOI: 10.1177/00031348261448903.Peer-Reviewed Original ResearchBreast-conserving surgeryRate of margin positivityInvasive breast carcinomaConservative surgeryMarginal excisionStudy groupPositive marginsRe-ExcisionBreast carcinomaControl groupSpecimen radiographyRisk of local recurrenceAdequate negative marginsComplete marginal excisionIntraoperative specimen radiographyRe-excision ratesFisher's exact testWilcoxon rank sum testRank sum testFinal pathologyNegative marginsLocal recurrenceShave marginsLumpectomy specimensTumor markersIdentifying Disparities in Timely Receipt of Radiation After Breast‐Conserving Surgery
Reyes N, Ortega C, Mendiola A, Murray M, Fenton A, Brett-Morris A, Mangira C. Identifying Disparities in Timely Receipt of Radiation After Breast‐Conserving Surgery. The Breast Journal 2026, 2026: 9942451. PMID: 41641173, PMCID: PMC12865119, DOI: 10.1155/tbj/9942451.Peer-Reviewed Original ResearchConceptsBreast-conserving surgeryStage I-III breast cancerI-III breast cancerAdjuvant radiationDefinitive surgeryBreast cancerRetrospective analysisRetrospective analysis of womenPatients of white raceInitiation of radiationPatients of black raceReceipt of radiationSurgery to initiationBreast Cancer RegistryComparison to patientsInsurance statusBreast cancer treatmentRecommended time frameAnalysis of womenAdjuvant chemo-Local recurrenceRadiation therapyCommission on CancerFinal surgeryCancer Registry
2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
Pellicane J, Beitsch P, Rock D, Budway R, Dul C, Kelemen P, Ashikari A, Baron P, Weinstein P, Mislowsky A, Lee L, Beatty J, Murray M, Dupree B, Finn C, Corcoran K, Wang S, Menicucci A, Yoder E, Blumencranz L, Dauer P, Audeh W, Whitworth P, Group N. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer. Surgical Oncology 2022, 45: 101885. PMID: 36436423, DOI: 10.1016/j.suronc.2022.101885.Peer-Reviewed Original ResearchConceptsNeoadjuvant endocrine therapyEarly-stage breast cancerPathological partial responsePatients treated with neoadjuvant endocrine therapyTreated with neoadjuvant endocrine therapyB type tumorsLong-term outcomesEndocrine therapyOverall survivalBreast cancerHER2- tumorsNeoadjuvant therapyStable diseaseB tumorsClinical benefitResponse to neoadjuvant endocrine therapyLuminal B type tumorsAssociated with tumor responsePrognostication of long-term outcomesResponse to neoadjuvant therapyLuminal A-typeMolecular subtype signaturesPost-operative chemotherapyPartial responseTumor responseGenomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Whitworth P, Beitsch P, Murray M, Richards P, Mislowsky A, Dul C, Pellicane J, Baron P, Rahman R, Lee L, Dupree B, Kelemen P, Ashikari A, Budway R, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci A, Yoder E, Finn C, Blumencranz L, Audeh W. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. JCO Precision Oncology 2022, 6: e2200197. PMID: 36108259, PMCID: PMC9489196, DOI: 10.1200/po.22.00197.Peer-Reviewed Original ResearchConceptsPathologic complete response ratePathological complete responseHER2-Targeted TherapySecondary end pointsHuman epidermal growth factor receptor 2 (HER2)-positive tumorsDistant metastasis-free survivalEarly-stage breast cancerMolecular subtype signaturesHER2-positive patientsMetastasis-free survivalOverall survival differenceGenomic classificationFluorescence in situ hybridizationHER2-typeComplete responseNeoadjuvant chemotherapyNeoadjuvant therapyHER2-positiveLuminal tumorsOverall survivalDual therapySYMPHONY trialsClinical outcomesSurvival differencesBreast cancerOmission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care
Hong MJ, Lum SS, Dupont E, Howard-McNatt M, Chiba A, Levine EA, Gass JS, Gallagher K, Fenton A, Murray M, Solomon NL, Ollila DW, Lazar M, Namm JP, Walters LL, Chagpar AB, Investigators S. Omission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care. Journal Of Surgical Research 2022, 279: 393-397. PMID: 35835032, DOI: 10.1016/j.jss.2022.06.036.Peer-Reviewed Original ResearchConceptsAdjuvant radiationBreast cancerNational Comprehensive Cancer Network guidelinesMean tumor sizeLevel I evidenceMajority of patientsInvasive breast cancerLow-grade diseaseBreast cancer patientsOmission of radiationBreast cancer treatmentRadiation useEligible patientsEndocrine therapyConservative treatmentBreast conservationNetwork guidelinesTumor sizeI evidenceMean ageCancer patientsSubgroup analysisStage 0Radiation therapyPatientsDistinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Murray M, Gittleman M, Budway R, Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precision Oncology 2022, 6: e2100463. PMID: 35476550, PMCID: PMC9200401, DOI: 10.1200/po.21.00463.Peer-Reviewed Original ResearchConceptsPathological complete responseTriple-negative breast cancerOverall survivalBreast cancerHER2- tumorsB tumorsBasal-typeMolecular subtype signaturesEstrogen receptor-positiveLuminal breast cancerNeoadjuvant treatment responseBreast cancer ageNeoadjuvant chemotherapy responseLong-term survivalNeoadjuvant regimensNeoadjuvant therapyResidual diseaseComplete responseA tumorsReceptor-positiveChemotherapy responseMolecular subtypesSYMPHONY trialsBreast tumorsProspective studyASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Nash C, Murray M, Richards P, Gittleman M, Budway R, Layeequr Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Annals Of Surgical Oncology 2022, 29: 4153-4154. DOI: 10.1245/s10434-022-11711-0.Peer-Reviewed Original ResearchAge-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Nash C, Murray M, Richards P, Gittleman M, Budway R, Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Annals Of Surgical Oncology 2022, 29: 4141-4152. PMID: 35378634, PMCID: PMC9174138, DOI: 10.1245/s10434-022-11666-2.Peer-Reviewed Original ResearchEarly-stage breast cancerBreast cancer patientsMenopausal statusOverall survivalBreast cancerCancer patientsLow riskHigh riskEarly-stage breast cancer patientsHER2-type tumorsLuminal A-typeLuminal B typeMammaPrint-high riskMolecular subtype signaturesPost hoc subanalysisPathological complete responseHigh-risk tumorsBasal-type tumorsFollow-up resultsLong-term outcomesComplete responseNeoadjuvant chemotherapyProspective trialsPatient ageNo significant differenceDoes Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy?
Horattas I, Fenton A, Gabra J, Mendiola A, Li F, Namm J, Solomon N, Gass J, Lum S, Murray M, Howard-McNatt M, Dupont E, Levine E, Brown E, Ollila D, Chiba A, Chagpar AB. Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy? The American Surgeon 2022, 88: 1607-1612. PMID: 34982015, DOI: 10.1177/00031348211069783.Peer-Reviewed Original ResearchConceptsCavity shave marginsMargin statusPartial mastectomyMolecular subtypesBreast cancer stage IOverall positive margin rateStandard partial mastectomyBreast-Conserving TherapyCancer stage IInvasive breast cancerImpact of subtypePositive margin rateBreast cancer subtypesLymphovascular invasionSurgical therapySystemic therapyRandomized trialsSurgical marginsShave marginsInvasive carcinomaMargin rateBreast cancerHispanic ethnicityStage IPatients